Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.52 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.44 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7477006 | 0.89 | SERPINE1 (0.51) | PPARGSERPINE1NTSR1 | |
| SCHEMBL7482851 | 0.87 | PPARG (0.51) | PPARGSERPINE1NTSR1 | |
| SCHEMBL14233800 | 0.84 | PPARG (0.70) | PPARG | |
| SCHEMBL7524721 | 0.80 | KMT2A (0.57) | — | |
| SCHEMBL7475482 | 0.80 | POLB (0.44) | PPARGSERPINE1TSHR | |
| SCHEMBL7473999 | 0.79 | PPARG (0.49) | PPARGTSHR | |
| SCHEMBL27583578 | 0.79 | SERPINE1 (0.41) | PPARGSERPINE1NTSR1 | |
| SCHEMBL28566467 | 0.79 | PLAU (0.56) | PPARG | |
| SCHEMBL28565969 | 0.79 | PPARG (0.53) | PPARGTSHR | |
| SCHEMBL14121203 | 0.79 | PPARG (0.50) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1379774-A | Compounds | ASTRAZENECA AB (SE) | 2002-11-13 | — | — | CN | disclosed |
| EP-1210343-A2 | BENZOIC ACID DERIVATIVES AND THEIR USE AS PPAR RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012187-A2 | BENZOIC ACID DERIVATIVES AND THEIR USE AS PPAR RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-02-22 | — | — | WO | disclosed |